Monosodium urate (MSU) deposits detected by dual-energy computed tomography (DECT) are common in patients with gout and are associated with higher coronary calcium scores, researchers recently reported in JAMA Cardiology.
The suggestion that DECT scans might add to our diagnostic ability to detect cardiac disease may be imprudent because we have tests at our disposal and have little need to increase diagnostic costs. Good clinical judgement, paying attention to traditional risk factors and to red flags, will increase the number of asymptomatic cardiac patients we choose to study with conventional methods.
Rheumatoid arthritis and type 2 diabetes mellitus share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes. In this slideshow, we highlight some of the similarities.
Insulin resistance is independently associated with body mass index and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.
2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
Studies that explore the efficacy and safety of JAK inhibitors for rheumatoid arthritis are among those we selected as most noteworthy in 2019. Also, at the top of the list, a study that shows glucocorticoids, not necessarily biologics, raise the infection risk after joint replacement surgery. Learn more in this slideshow.
There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements.
In this slideshow, we review the year's most noteworthy new books in rheumatology as selected by BookAuthority.com. This is by no means a comprehensive list, but it offers a good look at the diverse selections of rheumatology books published this year.
Step therapy policies may be blocking timely access to care for rheumatology patients, finds a new report by Xcenda, an AmerisourceBergen company. The report finds that patients are more likely to be nonadherent or pay out of their own pocket for drugs. Learn more in this slideshow.
Xcenda, an AmerisourceBergen company, has just published a white paper that demonstrates the prevalence of step therapy and its potential negative impact on rheumatology patients. The authors of the report say the practice doesn’t always have the best interest of patents in mind and payers don't entirely disagree. Learn more in this report.
Intra-articular administration of sprifermin statistically increases total femorotibial joint cartilage thickness in individuals with symptomatic radiographic knee osteoarthritis, but the clinical importance and duration of the effect are uncertain, say researchers writing recently in JAMA.
Blood clots can cause critical or lethal problems in patients, and individuals with antiphospholipid syndrome can experience these events at any location in their bodies. However, there’s not a great deal of clarity on which risk factors are most significant for this condition. In this Q&A, we feature a conversation with Eileen J. Lydon, ANP-BC, a rheumatology nurse practitioner at New York University Langone Orthopedic Hospital, who recently spoke on recommendations for treating patients with antiphospholipid syndrome.
Among the most noteworthy in 2019: Treatment of rheumatologic diseases with interleukin inhibitors may raise patients’ risks for serious and opportunistic infections and possibly also cancer, researchers reported in JAMA Network Open in October.
Among the year's most noteworthy findings in rheumatology, includes a systemic review and meta-analysis that provides a better understanding of how common infections and cancer really are in patients treated with interleukin (IL) inhibitors. In this article, Dr. Murray offers his personal perspectives on the findings.
Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.